Orthocell (ASX: OCC) is stepping up its global game, announcing the first sales of its flagship dental regeneration product, Striate+™, in the high-potential DACH region — Germany, Austria, and Switzerland….
KMD Brands Battles Tough Trading, Leans into Direct-to-Consumer Growth
KMD Brands, the parent company of Kathmandu, Rip Curl, and Oboz, has handed down its first-half FY25 results — and it’s a mixed bag. While sales held steady at $470.9…
Clinuvel Reports Promising Stroke Trial Results for PRÉNUMBRA Instant
Clinuvel Pharmaceuticals has shared some encouraging early data from its latest stroke study, with results suggesting its experimental treatment, PRÉNUMBRA Instant, could offer hope to patients who aren’t eligible for…
Black Cat Starts Mining at Boundary Ahead of Schedule
Black Cat Syndicate (ASX: BC8) is off to a fast start in 2025, with mining officially underway at the Boundary open pit—well ahead of schedule. This forms part of the…
Meridian Greenlights $227M Ruakākā Solar Farm – Construction Starts August 2025
Meridian Energy (NZX: MEL) is charging ahead with its first New Zealand solar project, approving a $227 million investment to build the 130MW Ruakākā Solar Farm just south of Whangārei….
Immutep Doses First Patient in Landmark Phase III Trial for Lung Cancer
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has officially dosed the first patient in its pivotal Phase III TACTI-004 trial, marking a major milestone in the company’s development of eftilagimod alfa…
Catalyst Expands Trident Footprint with High-Grade Gold Hits at Depth
Catalyst Metals (ASX: CYL) has reported a promising update from the Trident Gold Project, where recent step-out and infill drilling has significantly expanded the mineralised footprint — and unveiled the…
4DMedical Wraps Up Oversubscribed $8.4M SPP, Secures $13.9M in Fresh Funding
Respiratory imaging innovator 4DMedical (ASX: 4DX) has successfully completed its Share Purchase Plan (SPP), raising $8.4 million — well above the original $7 million target. This follows the company’s earlier…
Neurizon Prepares for HEALEY ALS Trial with Promising Respiratory Results from NUZ-001
Neurizon Therapeutics (ASX: NUZ & NUZOA) has taken a significant step forward in its fight against ALS, unveiling a promising respiratory outcome from its lead drug candidate, NUZ-001, and sharing…
Helia Confirms CBA Contract Set to End in 2025
Helia Group Limited (ASX: HLI) has announced that its long-standing partnership with the Commonwealth Bank of Australia (CBA) is likely coming to an end. CBA has advised that it has…